Epigenetic inactivation of PCDH10 in human prostate cancer cell lines

Authors

  • Zesong Li,

    Corresponding author
    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    2. Shenzhen Second Peoples Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, Peoples Republic of China
    Search for more papers by this author
  • Wenjie Li,

    Corresponding author
    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    2. Shantou University Medical College, Shantou 515041, Peoples Republic of China
    Search for more papers by this author
  • Jun Xie,

    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    Search for more papers by this author
  • Yong Wang,

    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    Search for more papers by this author
  • Aifa Tang,

    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    2. Shenzhen Second Peoples Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, Peoples Republic of China
    Search for more papers by this author
  • Xianxin Li,

    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    Search for more papers by this author
  • Jiongxian Ye,

    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    Search for more papers by this author
  • Yaoting Gui,

    Corresponding author
    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    Search for more papers by this author
  • Zhiming Cai

    Corresponding author
    1. Guangdong Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Shenzhen PKUHKUST Medical Center, Shenzhen 518036, Peoples Republic of China
    2. Shenzhen Second Peoples Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, Peoples Republic of China
    Search for more papers by this author

Zesong Li and Wenjie Li contributed equally to this work.

To whom correspondence should be addressed (email caizhiming2000@yahoo.com.cn or guiyaoting2007@yahoo.com.cn).

Abstract

PCDH10 (protocadherin-10), a novel tumour suppressor gene, is down-regulated in several human cancers due to hypermethylation of promoter CGIs (CpG islands). Here, we investigated the expression of PCDH10 in different normal adult tissues and in a panel of prostate cancer cell lines. PCDH10 was widely expressed in normal tissues with higher levels in the prostate. The expression of PCDH10 was markedly reduced or silenced in prostate cancer cell lines compared with normal adult prostate tissue. Decreased PCDH10 expression was correlated with the methylation status of the PCDH10 promoter. Furthermore, the DNA demethylating agent 5′-azacytidin restored PCDH10 expression by suppressing PCDH10 promoter methylation in prostate cancer cell lines. Treatment with Trichostatin A alone had no significant effect on the expression of PCDH10 but enhanced the effect of 5′-azacytidin. In conclusion, we found that the decreased PCDH10 expression in prostate cancer cells was associated with the aberrant methylation of PCDH10 promoter CGI. Our results may contribute to the understanding of the role of PCDH10 inactivation in the progression of prostate cancers.

Ancillary